CATALYSTYahoo Finance • 14h ago
Amylyx Pharmaceuticals And 2 More Quality Growth StocksYahoo Finance report covering Amylyx Pharmaceuticals Inc. (AMLX) market action, institutional positioning, and fundamental catalysts.
Why AMLX Stock advanced +0.63% Today — RQD Quant Desk Flash
$28.86 +0.63% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $28.84
Amylyx Pharmaceuticals Inc. (AMLX) carries a Roarable Rating of D- (Sell) with 39/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE D- • RED ALERT
Cap $3.60B
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER
Click Any Pre-Computed AI Quant Specialist Briefing on AMLX Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is AMLX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-02, Amylyx Pharmaceuticals Inc. (NASDAQ: AMLX) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 39/100 at a spot price of $28.86 (+0.63% 1D, market cap $3.60B). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 10/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, AMLX ranks #543 in composite RQD confidence.
✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does AMLX compare to ACAD and OGN in the Health Care sector?
▼
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), AMLX carries a Roarable D- (39/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, ACAD (ACADIA Pharmaceuticals Inc.) holds a D grade (50/100 RQD, P/E 9.1x, ROIC 7.9%, cap $3.58B) and OGN (Organon & Co.) posts a B- grade (70/100 RQD, P/E 19.4x, ROIC 24.9%, cap $3.63B). Among the 5-stock peer group, ACAD leads on earnings multiple (9.1x) while OGN leads on capital efficiency (24.9% ROIC).
✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for AMLX?
▼
Per AMLX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001658551), Amylyx Pharmaceuticals Inc. generated $0 in revenue (-100.0% YoY), -$144.7M in net income, and -$123.5M in free cash flow against $332.6M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $28.84 (-0.08%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 6/20 (E) • 0% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record Warning: Scores below 50 (39/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-7.6% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERRED ALERT • D-
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw E · Rk D
Each axis scored 0–20
12M PRICE TARGET CONE-8.6% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for AMLX)Realized 20D OHLCV Swing Band: ±10.1%
Deterministic 5-Pillar Attribution (39/100 Composite)
🔍 WHY AMLX SCORES 39/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Whale & Options Positioning+10/20 pts (26% of score)
20D Institutional Volume Accumulation (±10.1% realized swing band)
▲ #2 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (26% of score)
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 3/9
▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)
Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade E$27.48-0.5% Next Q
31
Q2 (-2Q)Grade E$27.33-0.9% Next Q
34
Q3 (-1Q)Grade E$27.09+6.5% Next Q
36
CurrentGrade D-$28.86-7.6% Hist 90D α
39
Trajectory: E (31) → D- (39)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a AMLX Turnaround Squeeze
While AMLX currently carries a cautious 39/100 (D-) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Established market leader in Health Care with deep daily trading liquidity.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($30.69) and Max Pain ($30.30) forces dealer call-delta covering toward $43.20.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $AMLX• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “AMLX Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why AMLX Stock advanced +0.63% Today — RQD Quant Desk Flash
Amylyx Pharmaceuticals Inc. (AMLX) advanced +0.63% to $28.86, trading at 59% of its 52-week range ($10.83 – $41.14). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 59% of its 52-week range ($10.83 – $41.14) with RSI-14 at 50.8 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±10.1% around $28.86 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable D- (Sell) backed by 52% gross margin and $0 annual free cash flow.
Live AMLX Headlines & Catalysts
MARKET WIRETradingView • 17h ago
Amylyx Pharmaceuticals, Inc. Estimates – NASDAQ:AMLXTradingView report covering Amylyx Pharmaceuticals Inc. (AMLX) market action, institutional positioning, and fundamental catalysts.
MARKET WIRESimply Wall St • 20h ago
Amylyx Pharmaceuticals (NasdaqGS:AMLX) Stock Forecast & Analyst PredictionsSimply Wall St report covering Amylyx Pharmaceuticals Inc. (AMLX) market action, institutional positioning, and fundamental catalysts.
MARKET WIREStock Titan • 23h ago
A live call will cover Amylyx's third-quarter results on Nov. 5 at 8 a.m. ET.Stock Titan report covering Amylyx Pharmaceuticals Inc. (AMLX) market action, institutional positioning, and fundamental catalysts.
MARKET WIREBenzinga • 1d ago
Amylyx Pharma Q2 2026 Earnings Call TranscriptBenzinga report covering Amylyx Pharmaceuticals Inc. (AMLX) market action, institutional positioning, and fundamental catalysts.
CATALYSTTradingView • 1d ago
Amylyx Pharmaceuticals, Inc. Stock 12‑Month Price Target Raised to $43, Implies 59% UpsideTradingView report covering Amylyx Pharmaceuticals Inc. (AMLX) market action, institutional positioning, and fundamental catalysts.
MARKET WIREMarketBeat • 1d ago
Amylyx Pharmaceuticals (AMLX) Short Interest & Short Float | Updated Oct 2026MarketBeat report covering Amylyx Pharmaceuticals Inc. (AMLX) market action, institutional positioning, and fundamental catalysts.
MARKET WIRESimply Wall St • 1d ago
Will Phase 3 Trial Data Change Amylyx Pharmaceuticals Stock NarrativeSimply Wall St report covering Amylyx Pharmaceuticals Inc. (AMLX) market action, institutional positioning, and fundamental catalysts.
CATALYSTYahoo • 7d ago
Can Corcept Therapeutics Stock Rally 40% After This Dip?For questions about this article or underlying research, email help@trefis.com.
CATALYSTBenzinga • 18d ago
Citigroup Maintains Buy on Amylyx Pharmaceuticals, Raises Price Target to $39Citigroup analyst Geoff Meacham maintains Amylyx Pharmaceuticals (NASDAQ:AMLX) with a Buy and raises the price target from $32 to $39.
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring AMLX)
- ✓Walkthrough of AMLX's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
AMLX // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +75.33%🛡️ HOLDING TREND SUPPORT
2026-11-02O $28.07H $28.86L $28.07C $28.86VOL 905.5K
RES: $36.71SUP: $27.35SMA50: $30.69SMA200: $20.15
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
AMLX Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on AMLX today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for AMLX. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for AMLX today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (AMLX)
Health Care Rank #543 of 1016
⚔️ ACAD vs AMLX Full Matrix →
1. Head-to-Head Health Care Peer Comparison (AMLX vs. ACAD, OGN, XENE, IRON)
Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, Amylyx Pharmaceuticals Inc. (AMLX) ranks #543 by composite RQD confidence (39/100, grade D-) and #192 by equity capitalization ($3.60B). Within this direct 5-issuer industry benchmark cohort, ACAD leads on earnings valuation at 9.1x trailing P/E, while OGN leads on capital efficiency and profitability with 24.9% ROIC and 53.3% gross margin. OGN currently holds the highest overall quantitative score in the immediate peer group at 70/100 (B-) compared with AMLX at 39/100 (D-).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| AMLX
ACTIVE
Amylyx Pharmaceuticals Inc. | D- | 39/100 | — | — | -35.0% | +0.63% | $3.60B | Benchmark Subject |
| ACAD ACADIA Pharmaceuticals Inc. | D | 50/100 | 9.1x | 91.7% | 7.9% | -0.82% | $3.58B | /acad-vs-amlx → |
| OGN Organon & Co. | B- | 70/100 | 19.4x | 53.3% | 24.9% | +0.22% | $3.63B | /ogn-vs-amlx → |
| XENE Xenon Pharmaceuticals Inc. | D- | 37/100 | — | — | -35.0% | -0.35% | $3.64B | /xene-vs-amlx → |
| IRON Disc Medicine Inc. | D+ | 54/100 | — | — | -27.5% | -2.41% | $3.68B | /iron-vs-amlx → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001658551In its most recent audited fiscal period (FY2025, filed 2025-12-31), Amylyx Pharmaceuticals Inc. (AMLX) reported GAAP revenue of $0 (-100.0% vs. FY2024 revenue of $87.4M , and -100.0% cumulative change since FY2023) , GAAP net income of -$144.7M, operating cash flow of -$123.3M, and free cash flow of -$123.5M (+26.4% YoY). On the balance sheet, AMLX closed FY2025 with $332.6M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 3/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $0 | -$144.7M | -$123.3M | -$123.5M | $332.6M | — |
| FY2024 (FY) | 2024-12-31 | $87.4M | -$301.7M | -$167.6M | -$167.8M | $193.6M | — |
| FY2023 (FY) | 2023-12-31 | $380.8M | $49.3M | $11.9M | $11.9M | — | — |
3. AMLX Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs AMLX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-02, Amylyx Pharmaceuticals Inc. (NASDAQ: AMLX) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 39/100 at a spot price of $28.86 (+0.63% 1D, market cap $3.60B). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 10/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, AMLX ranks #543 in composite RQD confidence.
How does AMLX compare to ACAD and OGN in the Health Care sector?
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), AMLX carries a Roarable D- (39/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, ACAD (ACADIA Pharmaceuticals Inc.) holds a D grade (50/100 RQD, P/E 9.1x, ROIC 7.9%, cap $3.58B) and OGN (Organon & Co.) posts a B- grade (70/100 RQD, P/E 19.4x, ROIC 24.9%, cap $3.63B). Among the 5-stock peer group, ACAD leads on earnings multiple (9.1x) while OGN leads on capital efficiency (24.9% ROIC).
What are the biggest fundamental strengths and SEC risk factors for AMLX?
Per AMLX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001658551), Amylyx Pharmaceuticals Inc. generated $0 in revenue (-100.0% YoY), -$144.7M in net income, and -$123.5M in free cash flow against $332.6M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is AMLX trading relative to its 50-day, 200-day, and 52-week technical levels?
AMLX last traded at $28.86 (+0.63% on volume of 989,547 shares), positioning the stock -5.96% below its 50-day simple moving average ($30.69) and +43.23% above its 200-day simple moving average ($20.15). Across its 52-week range of $10.83 to $41.14, AMLX sits at the 59.5% percentile with a 14-day RSI of 50.8 (NEUTRAL RANGE) and an implied next-earnings move of ±10.1% ($25.95 to $31.77).
AMLX Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is AMLX stock moving today?
Why AMLX Stock advanced +0.63% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
ROARABLE RATING BRIEF • RQD 39/100 (D-)
✓ STAGE-C NUMBER FIREWALL VERIFIED
AMLX — Amylyx Pharmaceuticals Inc.: What the Facts Mean to a Prospective Investor
Engine: anthropic/claude-haiku-5.5
As of: 2026-11-02T15:23:12Z
Roarable Rating Brief: What This Means to a Prospective Investor
Per the Roarable RQD rating, AMLX scores 39 out of 100 and carries a letter grade of D-, with the verdict label "Roarable Sell — Vulnerable Balance Sheet & Flow." The five pillars break down as follows:
- Fundamental Cash Engine: 6 / 20. This is the weakest contributor. The rating cites ROIC of -35% and an FCF yield of -3.43%, indicating that the business is currently consuming capital rather than generating it relative to its market value.
- Whale 13F Flow: 10 / 20. Institutional accumulation and options positioning are rated at a mid-range level. This is neutral-to-modestly supportive and does not by itself offset the fundamental weakness.
- Insider Conviction: 3 / 20. The SEC Form 4 and Congressional PTR cluster flow is rated very low, which suggests limited insider-level confidence signals in the data.
- Macro Regime Fit: 10 / 20. Beta is 1.0 and the rating notes sector sensitivity. The stock's market sensitivity is average, so it neither amplifies nor dampens broad market moves on this measure.
- Forensic Balance Sheet: 10 / 20. Per the rating, Altman Z is 2.5, Piotroski F is 3/9, and Debt/Equity is 0.5. These readings point to moderate balance-sheet strength on the Altman measure but weak operating-quality signals on Piotroski.
For a prospective investor evaluating the stock today, the rating's implication is that the cash-generation and insider-signal pillars are the primary drags, while institutional flow and balance-sheet metrics are only middling. Upside drivers would need to come from a turn in cash generation, which the current ROIC and FCF yield do not yet show. Valuation tradeoffs are difficult to assess directly because P/E and EV/EBITDA are unavailable in the source data, and the company reports negative earnings in the periods provided. The rating is a quantitative screen and is presented here for educational purposes, not as personalized financial advice.
Financial Trend
| Period | Revenue | Operating Income | Net Income | EPS | FCF | Cash | Debt |
|---|---|---|---|---|---|---|---|
| FY 2025 | $0.0M | $-153.3M | $-144.7M | N/A | $-123.5M | $226.7M | N/A |
| FY 2024 | $87.4M | $-314.7M | $-301.7M | N/A | $-167.8M | $77.4M | N/A |
| FY 2023 | $380.8M | $38.8M | $49.3M | N/A | $11.9M | N/A | N/A |
Per the SEC financials, operating and net results moved from positive in FY 2023 to substantial losses in both FY 2024 and FY 2025. Margins are reported as 0% for gross, operating, and net in the market data. Per the Roarable RQD rating, ROIC is -35%, and the Altman Z-Score is 2.5 and the Piotroski F-Score is 3/9. Reported cash rose from $77.4M to $226.7M between FY 2024 and FY 2025, and debt is marked N/A in the source data.
Recent Catalysts & News Wire Analysis
Per the news feed, the headlines include a Yahoo Finance report on the stock, a TradingView estimates item, a Simply Wall St forecast item, and a Stock Titan notice that a live call will cover third-quarter results on Nov. 5 at 8 a.m. ET. A Benzinga item references a Q2 2026 earnings call transcript. A TradingView item reports a 12-month price target raised to $43, which the headline states implies 59% upside. The news items are labeled as catalysts or market wire by the feed, with the price-target and Yahoo items flagged green.
Risk watch items per the source data: the upcoming third-quarter results call, and the reported losses and negative FCF in the financial trend. Per the Butterfly Supply-Chain Graph, the supply-chain value is NONE, there are no butterfly links, and there are no proprietary signals. Not available in source data for any additional proprietary signal.
Open Questions
- What are the company's specific revenue sources after FY 2023, given that reported revenue declined to $0.0M in FY 2025?
- What is the reason for the change in reported debt, which is marked N/A across all periods?
- What are the drivers of the increase in cash from $77.4M to $226.7M, and do they reflect operating or financing activity?
- What is the outcome of the third-quarter results call scheduled for Nov. 5?
- What are the EPS, P/E, and EV/EBITDA values, which are not available in the source data?
AMLX Live News Feed, Press Releases & Catalyst Wire
Real-time company headlines, analyst actions, and sector developments for Amylyx Pharmaceuticals Inc. (AMLX) • Click "Debate This Headline" to argue it in the Roar Pit below
🟢 CATALYST Yahoo Finance • 14h ago
Amylyx Pharmaceuticals And 2 More Quality Growth Stocks Yahoo Finance report covering Amylyx Pharmaceuticals Inc. (AMLX) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE TradingView • 17h ago
Amylyx Pharmaceuticals, Inc. Estimates – NASDAQ:AMLX TradingView report covering Amylyx Pharmaceuticals Inc. (AMLX) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Simply Wall St • 20h ago
Amylyx Pharmaceuticals (NasdaqGS:AMLX) Stock Forecast & Analyst Predictions Simply Wall St report covering Amylyx Pharmaceuticals Inc. (AMLX) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Stock Titan • 23h ago
A live call will cover Amylyx's third-quarter results on Nov. 5 at 8 a.m. ET. Stock Titan report covering Amylyx Pharmaceuticals Inc. (AMLX) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Benzinga • 1d ago
Amylyx Pharma Q2 2026 Earnings Call Transcript Benzinga report covering Amylyx Pharmaceuticals Inc. (AMLX) market action, institutional positioning, and fundamental catalysts.
🟢 CATALYST TradingView • 1d ago
Amylyx Pharmaceuticals, Inc. Stock 12‑Month Price Target Raised to $43, Implies 59% Upside TradingView report covering Amylyx Pharmaceuticals Inc. (AMLX) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE MarketBeat • 1d ago
Amylyx Pharmaceuticals (AMLX) Short Interest & Short Float | Updated Oct 2026 MarketBeat report covering Amylyx Pharmaceuticals Inc. (AMLX) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Simply Wall St • 1d ago
Will Phase 3 Trial Data Change Amylyx Pharmaceuticals Stock Narrative Simply Wall St report covering Amylyx Pharmaceuticals Inc. (AMLX) market action, institutional positioning, and fundamental catalysts.
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE
3 Active Posts & Replies
AMLX Bull vs. Bear Conversation Board — What's Your Call at $28.86?
🐂 33% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON AMLX 🐻 67% BEARISH CONVICTION
RO RoarDesk_Moderator Roarable Research Desk 🐻 BEARISH
🎯 Target: $25.24 (-12.0%)
📌 Pinned Debate 🔥 Official Bull vs. Bear Debate: Is AMLX (D- • RQD 39/100) a Buy at $28.68?
Welcome to the AMLX (Amylyx Pharmaceuticals Inc.) Roar Pit. Current RQD Composite is 39/100 (Roarable Sell — Vulnerable Balance Sheet & Flow) in Biotechnology: Pharmaceutical Preparations. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.
MU MultipleCompression Forensic Accounting Watch 🐻 BEARISH
🎯 Target: $24.09 (-16.0%)
Spot @ $28.68 Pump the brakes on AMLX — check the valuation vs. margin headwinds
Everyone in here is repeating the bull case on AMLX, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless Amylyx Pharmaceuticals Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.
SI SiliconVal_Bull Verified K Arena Trader 🐂 BULLISH
🎯 Target: $32.70 (+14.0%)
Spot @ $28.68 AMLX cash flow & RQD setup is being underpriced by the Street here
Looking at the 5-pillar RQD breakdown on AMLX, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $28.68 (52-wk range $10.83 - $41.14), any beat on forward guidance forces shorts and underweight funds to chase.